TCM
LCTX icon

Tradewinds Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Tradewinds Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$294 Buy
+224
New +$310 ﹤0.01% 669

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Tradewinds Capital Management's LCTX Position: Q2 2026 in Review

Tradewinds Capital Management opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 224 shares worth $294. The stake represents ﹤0.01% of the portfolio and ranks #669 among its holdings.

132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Tradewinds Capital Management held 224 shares of Lineage Cell Therapeutics worth $294 as of Q2 2026.
  • Lineage Cell Therapeutics was a new Tradewinds Capital Management position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Tradewinds Capital Management's portfolio in Q2 2026, its #669 holding.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Tradewinds Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.